Introduction
Folate is a vital vitamin that is found in meat, green vegetables, fruits and beans. The synthetic form added to foods and found in supplements is known as folic acid. Folate plays an essential role in several complex metabolic pathways, including those leading to the synthesis of DNA and RNA and those involved in methylation. Folate deficiency has been associated with slowed growth, anaemia, weight loss, digestive disorders and some behavioural issues. Lowered folate has also been associated with increased risks of neural tube defects and folic acid supplementation is now commonly recommended during early pregnancy, pre-and post-conception. Many genes are involved in these metabolic pathways. In 1999, Jill James and colleagues [1] reported that a particular variant (polymorphism) of one of these genes (methylenetetrahydrofolate reductase; MTHFR) might be a maternal risk factor for having a child with Down syndrome and that a significant increase in plasma homocysteine levels exists in mothers of children with Down syndrome. This polymorphism is known to decrease the activity of MTHFR [2, 3] . This report stimulated considerable research into the possible significance of polymorphisms in MTHFR and other enzymes involved in one carbon and transsulfuration (1-C/TS) metabolism ( Figure 1 ) in mothers and affected individuals with Down syndrome in altering the likelihood of birth of a child with Down syndrome ( Table  1) . This issue remains unresolved. In this issue, Kohli et al. [22] make a contribution to this debate. They find that the C677T MTHFR polymorphism is not associated with increased risk of having a child with Down syndrome in young mothers of Northern Indian origin. They also measured plasma homocysteine levels and found these to be lower in mothers of children with Down syndrome than in mothers of children without Down syndrome. This manuscript presents an opportunity to consider the current status of work in this field and to offer some thoughts on the future of studies to resolve the remaining issues.
Since the initial report of James [1] there have been at least 19 studies on possible polymorphisms not only in the MTHFR gene but also in genes encoding other enzymes of 1-C/TS metabolism. These all included studies of the MTHFR gene, and many included studies of an additional MTHFR polymorphism, A1298C. Studies have been carried out on populations from North America, Brazil, Ireland, Denmark, France, Italy (Southern and Central), Spain, Japan, and Turkey in addition to India (Table 1) . Indeed, two additional studies have been carried out on the Indian population, one from Eastern India and one from Western India [11, 18] . A number of investigators now report that individual polymorphisms may be insufficient to cause an increased incidence of births of children with Down syndrome, but that a genotype in which two or more polymorphisms in different enzymes of the pathways may lead to increased incidence. Interestingly, some investigators are reporting that the presence of two polymorphisms in MTHFR, C677T and A1298C, when present together, lead to an increased risk. This includes a recent study from Rai et al., [18] on a population from Eastern India. Many investigators also hypothesise that there is a strong environment (primarily diet)-genotype interaction that makes studies difficult to compare and interpret.
To help unravel this situation, many investigators have begun to measure metabolites of 1-C/TS pathways, notably homocysteine levels. The rationale for this measurement is that abnormal or altered folate metabolism, including alterations caused by gene polymorphisms, can result in elevated homocysteine levels. Here again, the situation is unclear, since different investigators have reported that homocysteine levels are elevated, unchanged, or decreased in mothers of children with Down syndrome (Table 1) .
UPDATES
One interesting hypothesis regarding these observations is that folate can lower homocysteine levels so that dietary supplementation with folate might be expected to result in decreased incidence of births of children with Down syndrome, if elevated homocysteine is indeed associated with an increased incidence. Even here, the situation is unclear. Because perinatal folate supplementation has been shown to decrease the incidence of births with neural tube defects, some countries, notably the United States, have mandated supplementation of wheat flour based products with folic acid for a number of years (since 1998 in the United States). Therefore, it has been possible to examine the incidence of births of children with Down syndrome both prior to and after supplementation was initiated, and to check the effectiveness of supplementation by measuring folate levels in individuals pre-and post initiation of supplementation. When this is done, an elevation of serum and red blood cell folate is indeed observed post supplementation. However, there is no evidence of a decreased incidence of births of children with Down syndrome, and some studies actually provided evidence for a slight increase in incidence of births of children with Down syndrome, while other studies report no changes pre-and post-supplementation [23, 24, 25, 26] .
On the other hand, one report on maternal use of iron and folate during the first month of pregnancy indicates that folate use might decrease the incidence of births with Down syndrome [27] . In this case, folate tablets were taken, and the dose was higher than is likely to be attained by supplementation of the food supply. Some investigators have pointed out that altered folate metabolism might be expected to affect meiosis. This may present an added complexity to these studies, since about two-thirds of the non-disjunction events resulting in Down syndrome occur in meiosis I and therefore may occur, or at least be initiated, during the foetal development of the mother. This may mean that it would be the maternal grandmother whose genotype and diet might be significant. This information is essentially impossible to obtain [28, 29, 30] . Another possible complexity is that there are at least 7 genes on chromosome 21 that could be important for 1-C/TS Table 2) . Trisomy of these genes could well affect 1-C/TS metabolism. Genes encoding proteins that utilise reduced folate moieties might increase folate demand and in principle lead to functional folate deficiency in developing foetuses with Down syndrome. If the mother has impaired folate metabolism, it would then be the interaction of the mother and the developing foetus that would be of critical importance. Such an interaction has been hypothesised on the basis of preferential transmission of the MTHFR 677T allele to infants with Down syndrome [31] . From Table 2 , it is possible that NAMT1 (PRED28), GART, DNMT3L, and HRMT1L1 (PRMT2) could increase demand for 1-C units supplied by folate cofactors. However, recent studies suggest that only GART is likely to be of major importance. Ratel et al., [32] find evidence that methylated adenine is undetectable in mammalian DNA using an assay that could detect one methylated adenine/million DNA nucleotides. Moreover, they failed to detect any methylating function in the NAMT1 protein. DNMT3L is expressed in very limited developmental periods and only in a small number of tissues and has no methylating activity of its own. It enhances the activity of other DNA methylating enzymes [33] . Hence, it seems that it would not cause a significant increase in the need for 1-C groups. On the other hand, PRMT2 apparently does have protein methylating activity [34] . GART is a part of the de novo purine biosynthetic pathway, and trisomy of this gene may indeed elevate the need for 1-C units. Interestingly, individuals with Down syndrome have elevated purine levels in bodily fluids and this has been hypothesised to be due to trisomy of GART and resultant increased synthesis of purines [35, 36] . A number of investigators have speculated on the trisomy of the gene for cystathionine beta synthase (CBS), located on chromosome 21, in the possible role of enzyme polymorphisms and dietary response to folates [15, 20, 31, 37, 38] . CBS synthesises cystathionine from homocysteine and serine. Alternatively, homocysteine reacts with 5 methylFH 4glun to produce methionine and FH4 glun . 5-methylFH 4glun is considered a "methyl trap" because in the absence of homocysteine and/or a decrease in methionine synthase enzyme, it accumulates and cannot re-enter the 1-C/TS metabolic pathway. Lowered levels of serine, considered by many investigators to be a major methyl group donor through the action of serine hydroxymethyltransferase (SHMT), would also potentially decrease the supply of reduced FH 4glun compounds. [8] Brazil T allele C allele MTHFR 667T + MTHFR 1298C
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Another important gene located on chromosome 21 encodes the reduced folate carrier (RFC), widely considered to be quantitatively one of the most significant proteins involved in uptake of reduced folates from the diet and in cellular internalisation of reduced folates [39] . Indeed some investigators have looked for an association of polymorphisms in the RFC gene and the risk of birth of a child with Down syndrome [15, 17, 18, 19, 21] . In some reports, a G80A polymorphism in RFC, when present with the MTHFR polymorphism does seem associated with an increased incidence of births with Down syndrome [17, 19] . Increased RFC protein levels have been reported in foetuses with Down syndrome, so trisomy of this gene could increase the availability of reduced folates from the diet [40] . The gene for glutamate formiminotransferase (FTCD) is located on chromosome 21. This enzyme catalyses the synthesis of 5, 10 methenylF-H 4glun from formiminoglutamate (FIGLU) and FH 4glun . Thus, it might increase the availability of 1-C units. Indeed, reduced levels of FIGLU have been found in the amniotic fluid of pregnancies with Down syndrome [37] . Thus, an added complexity to the genotype of the mother is the possible effect of trisomy of these genes in the foetus with Down syndrome. In some cases, in principle, trisomy of these genes may have opposite effects, most notably for example trisomy for CBS may be hypothesised to decrease the availability of functional 1-C folate units, while trisomy of RFC may be hypothesised to increase the availability of these units. How can this situation be sorted out? Some suggestions are the following. It may be necessary to extend analysis of the effects of the observed polymorphisms to include more metabolites of the 1-C/ TS pathway, for example, at a minimum total serum and red blood cell folate levels. More informative would be analyses of the quantitative levels of all the folate compounds and related compounds, for example S-adenosyl homocysteine and S-adenosyl methionine. In this way one might be able to compensate for inevitable differences in diet and unknown or undetected polymorphisms in other genes encoding enzymes in 1-C/TS metabolism that are inherent in studies on humans. The concept here is that for polymorphisms to be of significance, they would almost certainly have to have a metabolic effect. What one would look for is a similar change in metabolism in cases of births of individuals with Down syndrome, a "metabolic signature" if you will, that could arise by a variety of different genetic or dietary alterations. Methods for combined genotyping and 1-C/TS metabolic phenotyping are being developed [41, 42] . These might be considered targeted metabolomic approaches. At another level of complexity, as is well recognised 1-C/TS metabolism is implicated in a wide variety of metabolic systems. It may be useful to apply the approaches of global metabolomic analysis to this problem.
Another possible approach is to undertake studies in mouse models. Mouse models exist for CBS, MTHFR, and RFC at least, and some studies have been undertaken. Mice offer the obvious advantages that diet and genotype can be rigorously controlled. Moreover, additional mouse models of relevance are being generated. For example, mutations corresponding to human polymorphisms in RFC and other genes implicated in humans can be produced. Clearly, the disadvantage is that it is not clear the extent to which observations in mice will be relevant to the human situation.
Fortunately, methods to apply all these approaches to this vexing problem are available and are rapidly becoming more accessible to researchers. It is likely that a combination of all the above approaches will be required. Since many investigators have hypothesised that alterations in 1-C/TS metabolism may play a role in the development of the intellectual disabilities, cardiac abnormalities, and increased risk of leukaemia seen in individuals with Down syndrome, it seems likely that understanding this crucial metabolic system will have dividends that extend far beyond unravelling the roles this metabolic system plays in altering the incidence of births of individuals with Down syndrome. 
